CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib and abemaciclib) and mammalian target of rapamycin (mTOR) inhibitors (everolimus) are effective agents for restoring endocrine sensitivity in patients with advanced breast cancer progression on prior aromatase inhibitors. We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hong-Wei, Huang, Li-Sheng, Xu, Qi-Ni, Wang, Hong-Biao, Li, Xu-Yuan, Lin, Jia-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344177/
https://www.ncbi.nlm.nih.gov/pubmed/30608416
http://dx.doi.org/10.1097/MD.0000000000013909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344177/
https://www.ncbi.nlm.nih.gov/pubmed/30608416
http://dx.doi.org/10.1097/MD.0000000000013909

Ejemplares similares